KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Basic): 2010-2025

Historic EPS (Basic) for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$1.87.

  • Nektar Therapeutics' EPS (Basic) rose 29.70% to -$1.87 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.63, marking a year-over-year increase of 153.15%. This contributed to the annual value of -$0.58 for FY2024, which is 60.00% up from last year.
  • Per Nektar Therapeutics' latest filing, its EPS (Basic) stood at -$1.87 for Q3 2025, which was up 36.61% from -$2.95 recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' EPS (Basic) registered a high of $8.69 during Q4 2024, and its lowest value of -$790 during Q4 2021.
  • Over the past 3 years, Nektar Therapeutics' median EPS (Basic) value was -$0.27 (recorded in 2023), while the average stood at -$0.40.
  • As far as peak fluctuations go, Nektar Therapeutics' EPS (Basic) plummeted by 121,438.46% in 2021, and later surged by 4,050.00% in 2024.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' EPS (Basic) stood at -$790 in 2021, then surged by 99.96% to -$0.32 in 2022, then soared by 31.25% to -$0.22 in 2023, then soared by 4,050.00% to $8.69 in 2024, then climbed by 29.70% to -$1.87 in 2025.
  • Its EPS (Basic) stands at -$1.87 for Q3 2025, versus -$2.95 for Q2 2025 and -$0.24 for Q1 2025.